natgillin/translations-raw huggingface dataset:
An Fc-containing molecule according to claim 1, having decreased affinity for FcY receptors as compared to a wildtype Fc, comprising an antibody Fc domain based on an IgG2 constant region, wherein amino acid residues 233, 234, 235, 237, and 238 defined by the EU numbering system, comprise a sequence selected from PAAAP, PAAAS, and SAAAS and further comprising mutations H268A or H268Q, V309L, A330S and P331S as defined by the EU numbering system. 
Molekula koja sadrži Fc prema zahtjevu 1, koja ima smanjen afinitet za FcY receptore u usporedbi sa Fc divljeg tipa, obuhvaćajući Fc domenu antitijela baziranu na IgG2 konstantnoj regiji, gdje aminokiselinski ostaci 233, 234, 235, 237, i 238 definirani EU sistemom numeracije, sadrže sekvencu izabranu iz PAAAP, PAAAS i SAAAS i dalje obuhvaćajući mutacije H268A ili H268Q, V309L, A330S i P331S kao što je definirano EU sistemom numeracije.
is the linker connected to the anti-DLL3 antibody; 
CBA je sredstvo za vezanje stanice koje je protutijelo anti-DLL3;
If administered to a pregnant woman, the present method reduces the development of abstinence in the fetus (and later in the newborn) while treating the pregnant mother for drug dependence. 
Ako se daje trudnoj ženi, ova metoda smanjuje razvoj apstinencije kod fetusa (i kasnije kod novorođenčeta) dok se trudna majka liječi od ovisnosti o drogi.
A compound of the formula: wherein: 
PATENTNI ZAHTJEVI 1. Spoj formule: bd
and R29 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, or taken together to form a carbocyclic or heterocyclic ring of 3 to 8 atoms; 
i R29 su nezavisno izabrani između H, alkil, supstituirani alkil, cikloalkil, supstituirani cikloalkil, aril, supstituirani aril ili uzeti zajedno tvore karbociklički ili heterociklički prsten od 3 do 8 atoma;
A preferred method according to embodiment 1 of aspect 2 or 3 is such that the genomic region of interest comprises one or more target nucleotide sequences in addition, and wherein in the amplification step (g) a primer is provided that hybridizes with the target nucleotide sequence and one or more primers are provided for the corresponding one or more additional target nucleotides, wherein the ligated DNA fragments are amplified, or circularized DNA is amplified, using the primers (embodiment 2 of aspect 2 or 3). 
Postupak građenja kontiga genomskog područja od interesa u skladu s patentnim zahtjevima 2 ili 3, naznačen time što genomsko područje od interesa sadrži jedan ili više ciljanih nukleotidnih sljedova uz, te što u koraku umnažanja (g) je osigurana početnica koja hibridizira s ciljanim nukleotidnim slijedom, te je osigurana jedna ili više početnica za odgovarajući jedan ili više dodatnih ciljanih nukleotida, gdje se ligirane fragmente DNA umnaža, ili se umnaža cirkulariziranu DNA, uz pomoć početnica.
The methanol solution from the hydrogenation reaction (18 g in 180 mL MeOH) was concentrated and switched to methyl t- butyl ether (MTBE) (45 mL). 
Metanolna otopina iz reakcije hidrogenacije (18 g u 180 mL MeOH) je ukoncentrirana i prebačena na metil butil eter (MTBE) (45 mL).
A is an organic cation of the formula (R5R6N=CH-NR7R8)+, wherein: R5, R6, R7 and R8 are independently selected from hydrogen, unsubstituted or substituted C1-C20 alkyl, and unsubstituted or substituted aryl; 
A je organski kation formule (RsRÂ«N=CH-NR;R:)*, pri čemu su Rs, R4, R; i Rg neovisno su odabrani od vodika, nesupstituiranog ili supstituiranog C,-C2galkila, i nesupstituiranog ili supstituiranog arila;
A Turkish coffee machine (1) according to Claim 1, characterized by a cooking chamber (2), which is positioned outside of the housing (15) and on the coffee cup section (14) in an alternative embodiment of the invention, cooks the coffee therein with pressurized steam and water provided through its upper surface, and enables to make a plurality of cups of coffee concurrently as the coffee that is cooked therein is distributed by the user to the cups. 
Aparat za tursku kavu (1) prema zahtjevu 1, naznačen komorom za kuhanje (2), koja se nalazi izvan kučišta (15) i na postolju za šalicu (14) u alternativnom ostvarenju izuma, kuha kavu pomoću pare pod pritiskom i vode dobivene kroz svoju gornju površinu, i omogućava pripremu više šalica kave istovremeno kako se skuhana kava raspodjeljuje od strane korisnika u šalice.
By “absence of microcrystalline cellulose” we mean that there is no or substantially no microcrystalline cellulose present within the matrix of the spheroids. 
gliceril monostearata, postoci prema težini su zasnovani na težini cijele jezgre sferoida, i polimerno vezivno sredstvo u odsustvu mikrokristalne celuloze.
The vaccine of claims 1-4, wherein one or more of the diphtheria toxoid, the tetanus toxoid, the killed whole-cell Bordetella pertussis, the two or more acellular pertussis components, the inactivated poliovirus type 1, the inactivated poliovirus type 2, or the inactivated poliovirus type 3 is absorbed onto aluminium hydroxide or aluminium phosphate or a mixture of both 
Postupak u skladu s patentnim zahtjevima 1-9, naznačen time što cjepivo sadrži IPV tipove 1, 2 1 3, adsorbirane na aluminijev hidroksid ili aluminijev fosfat ili smjesu istih, gdje se adsorciju provodi bilo prije miješanja s antigenom koji nije IPV, ili gdje se adsorciju provodi nakon miješanja s antigenom koji nije IPV.
A process for preparing a herbicidal composition as defined in claim 7, which comprises mixing the components a) and b) of the herbicidal mixture and further additives. 
Postupak za pripremu herbicidne smjese prema patentnom zahtjevu 7, koji sadrži miješanje komponenti a) 1 b) herbicidne smjese 1 dodatnih aditiva.
The adjustment of the idler gear 88 can, among other things, account for machining and assembly tolerances to provide a desired location and orientation of the gears to provide accurate and repeatable rotation of the spline shaft 40 and to reduce or eliminate backlash in the drive train 82. 
Podešavanje potpornog zupčanika (88) može, među ostalim, kompenzirati tolerancije obrade i sklapanja kako bi se postigla željeni položaj zupčanika za precizno ponavljajuće okretanje kuglasto-klinaste osovine (40) i da se smanji povratni trzaj u pogonskom mehanizmu (82).
Use of a compound according to any one of claims 1 to 29 for the manufacture of a medicament for use in the treatment of a metabolic-related disorder selected from: dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, and type 2 diabetes. 
Uporaba spoja prema bilo kojem zahtjevu od 1 do 29, naznačena time, da se koristi za izradu lijeka za uporabu u liječenju metabolički pripadajućeg poremećaja izabranog iz skupine koju čine: dislipidemija, ateroskleroza, koronarno srčano oboljenje, inzulinska rezistencija i dijabetes tipa 2.
Subsequently, once the stirred suspension had cooled, H2O (1L) was added prior to being extracted 4x with EtOAc. 
Zatim, nakon što se miješana suspenzija ohladila, dodana je H2O (1L) prije ekstrahiranja 4x sa EtOAc.
The present invention relates to a method and device for recycling a mixture of polymethylmethacrylate (PMMA) and/or acrylonitrile-butadiene-styrene (ABS) and crosslinked polymethylmethacrylate, in accordance with the introduction to the main claim. 
Predmetni izum se odnosi na postupak za recikliranje mješavine polimetilmetakrilata (PMMA) i/ili akrilonitril-butadien- stirena (ABS) s umreženim polimetilmetakrilatom, u skladu s uvodom u glavni patentni zahtjev.
Example 8: Crystallization of batch C6 (orthorhombic polymorph) 
Primjer 8: Kristalizacija serije C6 (ortorombski polimorf)
The method of claim 1, wherein the osteoblast differentiation medium contains dexamethasone, B-glycerol phosphate, ascorbic acid and bone morphogenic protein (BMP). 
Postupak sukladno zahtjevu 1, pri čemu je korak c) izveden pomoću medija koji sadrži deksametazon, ß-glicerol fosfat, askorbinsku kiselinu i koštani morfogeni protein (BMP).
less than 2.5 weight % of the total reaction mixture, and has an average molecular weight of 100,000 to 1,500,000 Daltons. 
(b) manje od 2,5%, težinski, od ukupne reakcijske smjese, te ima prosječnu molekulsku težinu od 100.000 do 1.500.000 Da.
The process of claim 1, wherein the acid is hydrochloric acid, and the oxycodone salt is oxycodone hydrochloride. 
Postupak prema zahtjevu 1, naznačen time da sastav oksikodon hidroklorida ima razinu 14-hidroksikodeinona manju od 5 ppm.
A process for the manufacture of a mixture of diastereomers of a 3-hydroxy-2-3 ethyl-4-[1,2,4]triazol-1-yl-3-phenyl-butyric acid ester derivative according to formula (I): 
PATENTNI ZAHTJEVI 1. Postupak za proizvodnju smjese diastereomera derivata estera 3-hidroksi-2-metil-4-[1,2,4]triazol-1-il-3-fenil-maslačne kiseline prema formuli (I):
the compound of formula (XVIII) is subjected to a condensation reaction with an amine RbNH2, Rb being as defined in Claim 1. 
spoj s formulom (XVIII) se podvrgava reakciji kondenzacije s aminom RbNH2, Rb je kako je definirano u zahtjevu 1.
is an optionally substituted C1-6 alkyl group, an optionally substituted phenyl group, or an optionally substituted 5- to 7-membered heterocyclic group which has 1 or 2 nitrogen atom(s) or sulfur atom(s), or R1 and R2 form, together with the nitrogen atom to which they are attached, an optionally substituted pyrrolidinyl group or an optionally substituted piperidinyl group; R3 is a methyl group; R4 is a fluorine atom or a chlorine atom; R5 is a hydrogen atom or a halogen atom; and R6 is a hydrogen atom, a halogen atom, a trifluoromethyl group or a methoxy group. 
Spoj aciltiouree prema zahtjevu 1 ili njegova sol, naznačen time, da je R' atom vodika ili metil skupina; R* je po izboru supstituirana C;.4 alkil skupina, po izboru supstituirana fenil skupina, ili po izboru supstituirana 5- do 7- člane heterociklička skupina koja ima 1 ili 2 atoma dušika ili atom(e) sumpora, ili R! i R* oblik, zajedno s atomom dušika na kojeg su vezani, po izboru supstituiranu pirolidinil skupinu ili po izboru supstituiranu piperidinil skupinu;
The immunogenic composition of claim 1 wherein the Hib conjugate is present in a lower saccharide dose than the saccharide dose of each of the at least two further bacterial saccharide conjugates. 
Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što konjugat Hib je prisutan u manjoj dozi saharida od doze saharida za svaki od najmanje dva dodatna konjugata bakterijskih saharida.
Use as claimed in claim 13, wherein R8 is H, methyl or ethyl. 
Spoj za uporabu prema zahtjevu 8, gdje R8 je H, metil ili etil.
(S)-1-amino-2-propanol (8.4 g, 0.112 mol) was added and the stirring was continued for 1 h at room temperature. 
Dodan je (S)-1-amino-2-propanol (8.4 g, 0.112 mol) te je nastavljeno s miješanjem tijekom 1 h na sobnoj temperaturi.
The immunogenic composition of claim 1 in which said adjuvant further comprises any one or more of a sterol, a lipopolysaccharide and 1,2-Dioleoyl-sn-Glycero-3-phosphocholine (DOPC). 
Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što navedeni adjuvans dodatno sadrži bilo koji od jednog ili više od sterola, lipopolisaharida i 1,2-dioleoil-sn-glicero-3-fosfokolina (DOPC).
allowing crystalline form I to form by cooling the dissolved protonated free base (e.g., at a temperature below 30°C). 
HR P20150327 T1 dopuštanje da se stvori kristalni oblik I hlađenjem otopljene protonirane slobodne baze (npr., pri temperaturi ispod 30*C).
lymphocytes by compounds of the invention: 
Broj objave europskog patenta:
3,4-Dichloro-benzenesulfonyl chloride (60 NL, 0.39 mmol) is added and the reaction mixture is stirred for 10 minutes at ambient temperature. 
Doda se 3,4-diklor-benzensulfonil klorid (60 ul, 0,39 mmolova) 1 reakcijsku smjesu se miješa 10 minuta pri sobnoj temperaturi.
The method according to claim 1, wherein Ar is a phenyl group, a naphthyl group, a pyridyl group, a quinolyl group, an isoquinolyl group, a thienyl group, a furyl group, a pyrrolyl group, a benzothienyl group, a benzofuryl group, an indolyl group, a thiazolyl group, a pyrimidinyl group, a quinazolynyl group, an imidazolyl group, a benzimidazolyl group, or a benzothiazolyl group, wherein Ar may be substituted by 1 to 3 halogen atoms, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group. 
Spoj ili sol prema zahtjevu 1, naznačen time, da je m 1. Spoj ili sol prema zahtjevu 1 ili 2, naznačen time, da je Ar fenilna skupina, naftil skupina, piridil skupina, kinolilna skupina, izokinolilna skupina, tienilna skupina, furilna skupina, pirolil skupina, benzotienil skupina, benzofurilna skupina, indolil skupinu, tiazolil skupina, pirimidinil skupina, kinazolinil skupina, imidazolil skupina, benzimidazolilna skupina ili benzotiazolilna skupina (pri čemu ti prstenovi mogu biti supstituirani sa 1 do 3 atoma halogena, C1 do C6 alkilnom skupinom, ili C1 do C6 alkoksi skupinom).
A glassy solid form of CDDO-methyl ester, having an x-ray powder diffraction pattern with a halo peak at approximately 13.5 °2θ, as shown in Figure 2C, and a Tg. 
Staklasto-kruti oblik CDDO metilnog estera, naznačen time da čiji rendgenski difraktogram praha ima amorfni halo na približno 13,5 °2θ, kao što je prikazano na Slici 2C, i koji ima Tg.
A pharmaceutical composition according to embodiment 14 in the form of a lyophilized powder or a frozen solution. A compound of formula (I) wherein 
Farmaceutski pripravak u skladu s patentnim zahtjevom 12, naznačen time što je u obliku liofiliziranog praha ili smrznute otopine.
In yet another aspect the hydrogenation of a compound of formula (II) is conducted at a pressure of 1 to 10 bar, for example 2 to 4 bar. 
Postupak prema zahtjevu 9 naznačen time da se hidrogeniranje spoja formule (II) provodi na temperaturi u rasponu od 20 do 40*C.
The process according to claim 13, characterised in that the temperature is in the range of 20 to 32°C. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time što temperatura je u rasponu od 20 do 32 °C.
The modified IgG4 Fc fragment of claim 1, wherein the hinge region was mutated by the deletion of 1 to 8 continuous or discontinuous amino acid(s) comprising a Cys residue at the 8th position. 
Modificirani IgG4 Fc fragment prema zahtjevu 1, naznačeno time da je zglobna regija mutirana putem brisanja od 1 do 8 uzastopne/ih ili neuzastopne/ih aminokiselina sadržeći Cis ostatak na osmom položaju.
Figure 11 illustrates one embodiment of a mug-type container 1100 . 
Slika 11 prikazuje jedno ostvarenje posude tipa šalice 1100.
The method according to claim 1, wherein a rigid plastic plate-like construction is produced. The method according to claim 16, wherein the plate-like construction is self-supporting at span widths of up to 5,000 mm transverse to the central axes of the tube profiles and up to 20,000 mm in the direction of the central axes. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se proizvodi rigidna plastična ploča, pri čemu je osobito ploča samonosiva u rasponu širina do 5.000 mm poprečno u odnosu na središnje osi cjevastih profila i do 20.000 mm u smjeru središnjih osi.
The method of claim 1, wherein the amount of G-CSF in the buffered G-CSF composition of step (a) is in the range of from 0.1 mg/ml to 8.0 mg/ml. 
Postupak prema zahtjevu 1, naznačen time, da je količina od G-CSF u puferiranom G-CSF-sastavu iz koraka (a) u rasponu od 0,25 mg/ml do 6,5 mg/ml.
An isolated nucleic acid molecule encoding the VH and the VL of any one of the preceding claims. 
Izolirana molekula nukleinske kiseline koji kodira VH ili VL sukladno patentnom zahtjevu 2.
A compound for use according to claim 16 wherein the animal to be protected is a cat or dog and the parasitic invertebrate pest is a flea, tick or mite. 
Uporaba prema zahtjevu 7, naznačena time, da se kod životinje koja se treba zaštititi, radi o mački ili psu, a parazitni štetočina beskičmenjak je buha, krpelj ili rastoč.
A method for detecting antibodies against a B-AR in a sample comprising the step of contacting the sample with the cyclic peptide of claim 1 and detecting the presence or level of anti-B-AR antibodies in the sample based on binding to the cyclic peptide. 
Postupak detektiranja protutijela protiv B-AR (u uzorku), naznačen time što se sastoji u koraku stavljanja u kontakt cikličkog peptida u skladu s bilo kojim od patentnih zahtjeva 1 do 16 s navedenim protutijelima koja treba detektirati.
The method of claim 15, wherein the cell-free supernatant is dialyzed, lyophilized and reconstituted in a buffer or wherein the cell-free supernatant is dialyzed, desiccated and reconstituted in a buffer. 
Postupak u skladu s patentnim zahtjevom 15, naznačen time što se bestanični supernatant dijalizira, liofilizira i rekonstituira u puferu ili što se bestanični supernatant dijalizira, suši i rekonstituira u puferu.
A computer program product stored on a computer readable storage medium, which when run controls a mobile station apparatus (200) which is adapted to search a search space for a physical downlink control channel, PDCCH, transmitted by a base station apparatus, to perform the following steps, comprising: performing decoding processing, for searching the search space for the PDCCH, wherein the search space is defined based on a first mobile station identity, in a case that the mobile station apparatus has the first mobile station identity and a second mobile station identity; 
Postupak obrade u uređaju mobilne stanice koji pretražuje prostor pretraživanja za kontrolnim kanalom fizičke silazne veze, PDCCH, koji prenosi uređaj bazne stanice, naznačen time da postupak obrade sadrži: provođenje obrade slijepog dekodiranja, radi pretraživanja prostora pretraživanja za PDCCH, pri čemu je prostor pretraživanja određen na temelju identiteta prve mobilne stanice, u slučaju da uređaj mobilne stanice ima identitet prve mobilne stanice i identiteta druge mobilne stanice;
Me, Me or Et, Me) and wherein if the R2 column contains a value "--group--" such as "--cyclopropyl--", then both R2 values are taken together to be a spiro ring. 
Me, Me ili Et, Me) i naznačen time da ako je u stupcu R» navedena neka vrijednost "-skupina-" poput "-ciklopropil-", tada se obje vrijednosti R» zajedno uzimaju kao Å piro-prsten.
A composition comprising collagen covalently bound to particles, wherein covalent amide bonds are formed between free carboxylic acid groups of isolated or purified collagen and amine reactive groups of the particles, wherein the particles have an average particle diameter size ranging from 50 to 1000 nanometers, and wherein collagen is not cross-linked through the particles, and wherein the particles comprise ceramic material, biodegradable material, or metallic material of gold, silver, platinum, titanium, nickel, or copper. 
HR P20160275 T1 PATENTNI ZAHTJEVI Injektibilna ili implantabilna smjesa koja sadrži kolagen, kovalentno vezan na čestice, pri čemu se između slobodnih skupina karboksilne kiseline kolagena 1 reaktivnih amino skupina čestica stvaraju kovalentne amidne veze, a te čestice imaju prosječni promjer čestica u rasponu od 60 do 900 nanometara.
The system also foresees a semi-automatic mode in which the manipulator has an access interface for the operator comprising a control stick, provided with control buttons and possibly a display, which can also be provided with control buttons. In this way, the operator can directly bring about and follow the movements and the operations of the manipulator inside the store. System for moving crates in a warehouse in a hold of a ship, wherein the crates to be moved are organized in supply modules, each module made up of a predetermined number of rows, each having a predetermined number of crates, the system comprising: 
PATENTNI ZAHTJEVI Sustav za pomicanje sanduka u skladištu u skladišnom prostoru broda, pri čemu su sanduci (C) koji se trebaju pomicati organizirani tako da su postavljeni u module (M) za snabdijevanje, pri čemu se svaki od modula sastoji od unaprijed određenog broja redova, i pri čemu svaki od redova ima unaprijed određeni broj sanduka, pri čemu navedeni sustav ima najmanje jedan uređaj za pomicanje (1) redova sanduka, koji uređaj vrši pomicanje najmanje jednog reda sanduka na takav način da stvori najmanje jedan prolaz (W) radi prolaženja između jednog
Floor panel (24, 37, 41, 52, 70, 106, 114) as claimed in any of the foregoing claims, wherein the first locking element (31, 44, 53, 71) is positioned at a distance from an upper side (41d) of the upward tongue (25, 41, 56, 73). 
Podni panel (19, 24, 37, 41, 52, 70, 88, 97, 106, 114) prema bilo kojem od prethodno navedenih zahtjeva, naznačen time da je prvi element zaključavanja (31, 44, 53, 71, 89, 98) smješten na udaljenosti od gornje strane (41d) uvis okrenutog jezičca (25, 41, 56, 73).
The hop containing beverage according to the invention preferably contains at least 0.5 mg/kg, more preferably at least 1 mg/kg, even more preferably at least 3 mg/kg and most preferably at least 10 mg/kg of the pyrazine derivatives as defined herein before. 
Piće koje sadržava hmelj prema izumu poželjno sadržava najmanje 0,5 mg/kg, poželjnije najmanje 1 mg/kg, čak još poželjnije najmanje 3 mg/kg i najpoželjnije najmanje 10 mg/kg derivata pirazina kao što je ovdje ranije definirano.
An isolated monoclonal anti-Repulsive Guidance Molecule a (“RGMa”) antibody that comprises a variable heavy chain region comprising a complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:2, a CDR2 comprising the amino acid sequence of SEQ ID NO:3, and a CDR3 comprising the amino acid sequence of SEQ ID NO:4, and a variable light chain region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:6, a CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a CDR3 comprising the amino acid sequence of SEQ ID NO:8 or of SEQ ID NO:73. 
HR P20181087 T1 PATENTNI ZAHTJEVI Izolirano protutijelo monoklonske anti-odbojne vodljive molekule (RGMa) koje sadrži varijabilnu regiju teškog lanca koja sadrži regiju koja određuje komplementarnost (CDR) koja sadrži sekvencu aminokiseline SEQ ID NO:2, CDR2 koja sadrži sekvencu aminokiseline SEQ ID NO:3, i CDR3 koja sadrži sekvencu aminokiseline SEQ ID NO:4, i varijabilnu regiju laganog lanca koja sadrži CDRI1 koja sadrži sekvencu aminokiseline SEQ ID NO:6, CDR2 koja sadrži sekvencu aminokiseline SEQ ID NO:7, i CDR3 koja sadrži sekvencu aminokiseline SEQ ID NO:8 ili SEQ ID NO:73.
In particular, the central nervous system disorder is selected from the group of schizophrenia (in particular, negative symptoms or residual symptoms thereof), generalized anxiety disorder, bipolar disorder (I or II), migraine, behavioral and psychological symptoms of dementia, epilepsy or convulsive disorders, panic disorder, mixed anxiety and depression, and agoraphobia. 
Spoj ili farmaceutski pripravak za upotrebu prema zahtjevu 14 ili 15, naznačen time da je poremećaj središnjeg živčanog sustava odabran iz skupine koju čine shizofrenija (naročito njezini negativni simptomi ili rezidualni simptomi), opći anksiozni poremećaj, bipolarni poremećaj (I ili II), migrena, bihevioralni 1 psihički simptomi demencije, epilepsija ili konvulzivni poremećaji, panični poremećaj, miješana anksioznost i depresija, te agorafobija.
Prepare solutions of known concentration of p-toluenesulfonic acid, gemcitabine and the compound of Example 1. 
Pripravi se otopine poznatih koncentracija p-toluensulfonske kiseline, gemcitabina i spoja iz Primjera 1.
The slurry of any of claims 1 to 2 wherein the aluminum or aluminum alloy powder comprises a particle size distribution characterized in that the 50th percentile of the particle size distribution has a diameter of between 3.9 to 4.5 µm. and the 90th percentile of the particle size distribution has a diameter of less than or equal to 9.0 µm. 
Sastav obloge iz patentnog zahtjeva 7, pri čemu prah aluminija obuhvaća raspodjelu veličina čestica karakteriziranu na način da 50. percentila raspodjele veličine čestica ima promjer između 3.9 1 4.5 mikrometara i 90. percentila raspodjele veličine čestica ima promjer manji ili jednak 9.0 mikrometara.